NFATc2	O
enhances	O
tumor	O
-	O
initiating	O
phenotypes	O
through	O
the	O
NFATc2	O
/	O
SOX2	O
/	O
ALDH	O
axis	O
in	O
lung	O
adenocarcinoma	O
.	O
Tumor	B-TISSUE
-	I-TISSUE
initiating	I-TISSUE
cells	E-TISSUE
(	O
TIC	S-TISSUE
)	O
are	O
dynamic	O
cancer	B-TISSUE
cell	E-TISSUE
subsets	O
that	O
display	O
enhanced	O
tumor	O
functions	O
and	O
resilience	O
to	O
treatment	O
but	O
the	O
mechanism	O
of	O
TIC	S-TISSUE
induction	O
or	O
maintenance	O
in	O
lung	O
cancer	O
is	O
not	O
fully	O
understood	O
.	O


In	O
this	O
study	O
,	O
we	O
show	O
the	O
calcium	O
pathway	O
transcription	O
factor	O
NFATc2	O
is	O
a	O
novel	O
regulator	O
of	O
lung	B-TISSUE
TIC	E-TISSUE
phenotypes	O
,	O
including	O
tumorspheres	O
,	O
cell	O
motility	O
,	O
tumorigenesis	O
,	O
as	O
well	O
as	O
in	O
vitro	O
and	O
in	O
vivo	O
responses	O
to	O
chemotherapy	O
and	O
targeted	O
therapy	O
.	O


In	O
human	O
lung	O
cancers	O
,	O
high	O
NFATc2	O
expression	O
predicted	O
poor	O
tumor	O
differentiation	O
,	O
adverse	O
recurrence	O
-	O
free	O
and	O
cancer	O
-	O
specific	O
overall	O
survivals	O
.	O


Mechanistic	O
investigations	O
identified	O
NFATc2	O
response	O
elements	O
in	O
the	O
3	O
'	O
enhancer	O
region	O
of	O
SOX2	O
,	O
and	O
NFATc2	O
/	O
SOX2	O
coupling	O
upregulates	O
ALDH1A1	O
by	O
binding	O
to	O
its	O
5	O
'	O
enhancer	O
.	O


Through	O
this	O
axis	O
,	O
oxidative	O
stress	O
induced	O
by	O
cancer	O
drug	O
treatment	O
is	O
attenuated	O
,	O
leading	O
to	O
increased	O
resistance	O
in	O
a	O
mutation	O
-	O
independent	O
manner	O
.	O


Targeting	O
this	O
axis	O
provides	O
a	O
novel	O
approach	O
for	O
the	O
long	O
-	O
term	O
treatment	O
of	O
lung	O
cancer	O
through	O
TIC	S-TISSUE
elimination	O
.	O
